Benitec Biopharma Inc. (BNTC)
Benitec develops gene therapies for rare genetic diseases, led by a treatment candidate for oculopharyngeal muscular dystrophy. It last closed at $8.15 on Nov 17, down 4.57% on the day. BNTC reports earnings on Thu, Feb 11, 2027. The average 12-month price target from 3 analysts is $17.42 (+113.8% from the last close), with a high of $20.00 and a low of $14.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Key Stats
Last 12 monthsNot reported for this period.
From BNTC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on BNTC in the past 90 days. The average target is $17.42, with a high of $20.00 and a low of $14.00, compared with the last close of $8.15.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | Leerink Partners | Maintained | Buy | $18.27 |
| Nov 16 | Wedbush | Target raised | Buy | $17 → $20 |
| Oct 23 | Raymond James | Initiated | Buy | $14 |
| Sep 15 | Wedbush | Target raised | Buy | $16 → $17 |
| Jul 28 | Wedbush | Initiated | Buy | $16 |
Technical Analysis
The stock is 9% below its 20 day and 17% below its 50 day average. It is 39% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the swing low (Oct 19) at $8.00, and the nearest resistance the Pivot at $8.18.
| RSI (14) | 39.87 | Weak, oversold below 30 | Neutral |
| MACD | -0.16 | Below its signal line | Bearish |
| Stochastic | 28.0 | Middle of its range | Neutral |
| ADX (14) | 21.1 | Weak trend | |
| Williams %R | -93.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -149.6 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −3.0% | Change over 10 sessions | Bearish |
| ATR (14) | $0.68 | Typical daily range, 8.3% of price |
| RSI (14) | 36.88 | Weak, oversold below 30 | Neutral |
| MACD | -0.96 | Below its signal line | Bearish |
| Stochastic | 16.8 | Near the bottom of its range | Oversold |
| ADX (14) | 19.6 | No clear trend | |
| Williams %R | -95.7 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -94.7 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −33.1% | Change over 10 sessions | Bearish |
| ATR (14) | $1.50 | Typical daily range, 18.4% of price |
What happened before
See how BNTC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How BNTC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
Whale Options Flow
90DNo whale options trades in BNTC in the last 90 days.
BNTC Institutional Ownership
Full report →- ▲48 buying vs 32 selling
- ▼Held by funds -2.9 pts
- ▲Funds holding +4
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 91 | 87 | +4.6% |
| In funds' top 10 | 1 | 2 | −50.0% |
| Held by funds | 93.1% | 96.0% | −2.9 pts |
| New / increased | 15 / 33 | 11 / 36 | +2.1% |
| Reduced / sold out | 21 / 11 | 22 / 10 | 0.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BNTC is in one of them and how their past BNTC trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BNTC in an article yet. Here's the latest on the wider market.
About Benitec Biopharma
Benitec is a biotechnology company in Hayward, California, that develops genetic medicines for rare diseases. Its lead product candidate, BB-301, is a gene therapy being tested for oculopharyngeal muscular dystrophy, a degenerative muscle disorder that affects swallowing, eyelids and limbs. The company's approach uses viral vectors to deliver genetic material that silences a harmful gene while replacing it with a working copy. Its intended users are patients with this condition, and it may work with larger drug companies on some programs.
- Headquarters
- Hayward, CA


